The 2026 Q2 earnings cycle continues to roll alongside, with the reporting docket remaining stacked within the coming days and weeks. The interval has been one other one in every of positivity to this point, with a number of corporations, together with Abbott Laboratories ABT, Taiwan Semiconductor TSM, and Johnson & Johnson JNJ all reporting record-breaking ends in a method or one other.
ABT Shares Bounce Again
Abbott Laboratories posted a double-beat relative to our consensus expectations whereas additionally lifting its adjusted EPS steerage. Gross sales of $12.6 billion mirrored an all-time excessive for the corporate, rising by a double-digit 13% year-over-year.
Picture Supply: Zacks Funding Analysis
The inventory has bounced again by 15% over the previous month following a weak begin within the first half of the 12 months, with the current set of quarterly outcomes injecting positivity. The post-earnings response was the primary one in every of positivity that we’ve seen in current intervals, with the current earnings improve prone to hold momentum optimistic for the near-term.
Needless to say the inventory additionally gives a pleasant dividend payout, with shares at present yielding 2.4% yearly. Payouts have additionally grown constantly over its historical past, with ABT not solely a Dividend Aristocrat however a Dividend King as properly.
TSM Shares Face Volatility
Taiwan Semiconductor, a present Zacks Rank #2 (Purchase), has been caught up within the current weak spot we’ve seen amongst many main AI-related names, down 14% during the last month total. It manufactures the highly effective chips wanted to run next-generation AI applied sciences.
Gross sales of $40.2 billion in its current launch grew 33% YoY and mirrored a brand new document, with the corporate additionally elevating its full-year income development forecast to roughly 40%. TSM’s income has melted increased as of late, with the current $40.2 billion in quarterly gross sales reported almost doubling since 2024 Q2.
Picture Supply: Zacks Funding Analysis
JNJ Quietly Outperforms
Johnson & Johnson shares have quietly delivered an enormous acquire in 2026 to this point, up almost 30%. The three.2% acquire during the last month has equally proven good outperformance relative to the S&P 500, with the current outcomes resulting in optimistic momentum post-earnings.
Gross sales of $25.3 billion mirrored a brand new quarterly document for the corporate, rising by a stable 6.6% year-over-year. It additionally elevated each its present fiscal 12 months gross sales and adjusted EPS steerage, with JNJ now on observe to satisfy its 2026 goal of greater than $100 billion in annual income for the primary time in its historical past.
Picture Supply: Zacks Funding Analysis
Backside Line
The 2026 Q2 earnings season continues to roll alongside, and outcomes have been optimistic for a lot of corporations, together with Abbott Laboratories ABT, Taiwan Semiconductor TSM, and Johnson & Johnson JNJ. Not all corporations have seen nice post-earnings reactions, however the total earnings panorama stays one in every of energy.
The 2026 Q2 earnings season continues to roll alongside, and outcomes have been optimistic for a lot of corporations, together with Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson. Not all corporations have seen nice post-earnings reactions, however the total earnings panorama stays one in every of energy.
Past Nvidia: AI’s Second Wave Is Right here
The AI revolution has already minted millionaires. However the shares everybody is aware of about aren’t prone to hold delivering the most important earnings. AI’s second wave is transferring from infrastructure to implementation and these corporations are on the forefront of this transition, positioned to develop into what Amazon and Google have been to the web period.
Abbott Laboratories (ABT) : Free Inventory Evaluation Report
Johnson & Johnson (JNJ) : Free Inventory Evaluation Report
Taiwan Semiconductor Manufacturing Firm Ltd. (TSM) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
